Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination

In this phase 2 study, investigators evaluated the potential of two vaccines (H4:IC31 and BCG) to prevent the acquisition of tuberculosis infection and the subsequent development of sustained disease.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-07, Vol.379 (2), p.138-149
Hauptverfasser:	Nemes, Elisa, Geldenhuys, Hennie, Rozot, Virginie, Rutkowski, Kathryn T, Ratangee, Frances, Bilek, Nicole, Mabwe, Simbarashe, Makhethe, Lebohang, Erasmus, Mzwandile, Toefy, Asma, Mulenga, Humphrey, Hanekom, Willem A, Self, Steven G, Bekker, Linda-Gail, Ryall, Robert, Gurunathan, Sanjay, DiazGranados, Carlos A, Andersen, Peter, Kromann, Ingrid, Evans, Thomas, Ellis, Ruth D, Landry, Bernard, Hokey, David A, Hopkins, Robert, Ginsberg, Ann M, Scriba, Thomas J, Hatherill, Mark
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adolescents Antibodies, Bacterial - blood Antigens Bacillus Calmette-Guerin vaccine BCG BCG Vaccine - adverse effects BCG Vaccine - immunology Child Clinical significance Disease prevention Disease transmission Female HIV Human immunodeficiency virus Humans Immunization, Secondary Immunogenicity Infections Infectious diseases Male Medical research Mycobacterium tuberculosis - immunology Neonates Proportional Hazards Models Regression analysis Seroconversion Tuberculosis Tuberculosis - diagnosis Tuberculosis - prevention & control Tuberculosis - transmission Tuberculosis Vaccines - adverse effects Tuberculosis Vaccines - immunology Vaccine efficacy Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this phase 2 study, investigators evaluated the potential of two vaccines (H4:IC31 and BCG) to prevent the acquisition of tuberculosis infection and the subsequent development of sustained disease.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1714021